0.2%-0.3% General population (in the US) 2% Ashkenazi Jewish population 3% Women with breast cancer 6% Women with breast cancer onset < age 40 10% Women with ovarian cancer 20% High-risk families For women who have mutations in BRCA1 and/or BRCA2 genes, the risk for early breast cancer...
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC Related Articles Diagnostic Concordance in Interpreting Breast Biopsies See...
In some embodiments, the cancer is triple-negative metastatic breast cancer, including any histologically confirmed triple-negative (ER−, PR−, HER2−) adenocarcinoma of the breast with locally recurrent or metastatic disease (where the locally recurrent disease is not amenable to resection with ...
2. The method of claim 1, wherein said cancer is breast, ovarian or prostate cancer and said at least two markers are ferroportin and hepcidin wherein high ferroportin levels in the presence of low hepcidin levels are indicative of a lowered risk of recurrent disease. 3. The method of clai...
9. stool guaiac 10. IVP a. used to detect abnormal lung cells b. using a dye to visualize kidneys, ureters, and bladders c. visualization of abdominal lymph nodes d. tissue sample taken for microscopic examination e. tissue sample taken near a breast tumor ...
breast cancer, for example, tumor margins are of important significance to the surgical and radiation oncologists, but less important to the medical oncologist; menopausal status, on the other hand, is of substantially greater importance to the medical oncology specialty than to the surgical and ...
10.The method as claimed in claim 3, wherein said one or more chemotherapeutic agents are selected from the group consisting of 5 FU, CPT 11 and cisplatin. 11.The method as claimed in claim 3, wherein said cancer is cancer of colon, colorectal, breast, prostate, renal, lung or pancreas...